Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Theriogenology|February 16, 2005
Establishment of a specific radioimmunoassay for bovine interferon tauHitomi Takahashi, Masashi Takahashi, Hidekazu Nagaya, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 1, 2003
[Thalidomide therapy in patients with refractory or relapsed multiple myeloma]Naoya Ochiai, Chihiro Shimazaki, Ryo Uchida, et al.Annals of Transplantation|September 27, 2017
Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell TransplantationFumiaki Kitazawa, Shin-Ichi Fuchida, Yoko Kado, et al.Molecular and Clinical Oncology|February 20, 2016
The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicityFumiaki Kitazawa, Yoko Kado, Kumi Ueda, et al.Journal of Neurochemistry|June 11, 2004
Brain-specific potential guanine nucleotide exchange factor for Arf, synArfGEF (Po), is localized to postsynaptic densityYuji Inaba, Qing Bao Tian, Akira Okano, et al.Oncology Letters|July 12, 2017
Combination of lenalidomide and low-dose dexamethasone therapy promotes the anticoagulant activity of warfarin in patients with immunoglobulin light-chain amyloidosisFumiaki Kitazawa, Shin-Ichi Fuchida, Fumitaka Ise, et al.Japanese Journal of Clinical Oncology|June 20, 2002
Infusion of a high number of CD34+ cells provides a rapid hematopoietic recovery and cost savings in autologous peripheral blood stem cell transplantationEishi Ashihara, Chihiro Shimazaki, Akira Okano, et al.Biological & Pharmaceutical Bulletin|August 4, 2020
Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple MyelomaYoko Kado, Masayuki Tsujimoto, Shin-Ichi Fuchida, et al.International Journal of Hematology|February 6, 2020
A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in JapanShin-Ichi Fuchida, Daisuke Ide, Yoko Taminishi-Katsuragawa, et al.International Journal of Clinical Oncology|January 8, 2025
The real-world efficacy and safety of frontline therapy of obinutuzumab plus bendamustine for untreated high-tumor-burden follicular lymphomaHiroaki Nagata, Taku Tsukamoto, Tsutomu Kobayashi, et al.Pageof 8